Neoleukin Therapeutics, Inc. — Q2 2020 Form 10-Q
Entity note: The request identifies Neurogene Inc., but the supplied filing is for Neoleukin Therapeutics, Inc. The summary below reflects the filing.
Business context and reporting period
Unaudited results cover the quarter and six months ended June 30, 2020. Neoleukin is a pre-revenue biopharmaceutical company developing de novo protein-based immunotherapies. Its lead candidate, NL-201, remained in preclinical development; the company expected to submit an IND by the end of 2020.
Financial performance and liquidity
| Metric | Q2 2020 | Q2 2019 | Six months 2020 | Six months 2019 |
|---|---|---|---|---|
| Revenue | No product revenue reported | No product revenue reported | No product revenue reported | No product revenue reported |
| Research and development expense | $4.843 million | $(1.995) million | $10.341 million | $(1.891) million |
| General and administrative expense | $4.926 million | $2.423 million | $8.499 million | $4.978 million |
| Total operating expenses | $9.769 million | $0.428 million | $18.840 million | $3.087 million |
| Net loss | $9.746 million | $1,000 | $18.388 million | $2.209 million |
| Net loss per share, basic and diluted | $0.20 | Less than $0.01 | $0.37 | $0.09 |
Amounts are U.S. dollars; financial statement amounts are converted from thousands where applicable. Gross profit and operating margins are not meaningful because the company reported no product revenue.
- Cash and liquidity: Cash and cash equivalents were $129.6 million at June 30, 2020, down from $143.1 million at December 31, 2019. Working capital was $124.7 million; accumulated deficit was $317.9 million.
- Cash flow: Six-month operating cash outflow was $15.2 million, versus $4.2 million in 2019. Investing outflow was $1.1 million, mainly for laboratory and computer equipment. Financing inflow was $3.7 million, primarily from option exercises.
- Debt and obligations: The balance sheet reports no conventional borrowings. Total liabilities were $16.6 million, including operating and finance lease liabilities; operating lease liabilities totaled approximately $10.4 million.
Material changes versus the prior comparable period
- Operating expenses rose substantially as Neoleukin advanced NL-201 IND-enabling work and other platform programs. The 2019 comparison was unusually low because vendor-related restructuring recoveries reduced R&D expense after rosiptor development was halted.
- Q2 2020 G&A expense increased from $2.4 million to $4.9 million, reflecting higher personnel and professional-service costs following the merger, plus costs associated with terminating the Vancouver lease.
- Six-month net cash used in operations increased to $15.2 million from $4.2 million, consistent with higher development spending.
- Cash at June 30 was supplemented after quarter-end by a July 7 public offering that generated $71.4 million in net proceeds. On July 31, the company sold its Canadian subsidiary for $8.2 million in cash.
Outlook, commentary, risks, and unusual items
- Management said cash on hand together with the July offering proceeds was expected to fund planned operations into 2023. It cautioned that spending and funding needs could differ from forecasts and that additional capital may be required.
- COVID-19 had prompted remote work and stopped business travel from March 9. Business-critical research continued; management did not then expect development-plan delays but acknowledged possible effects on timing, vendors, and future clinical activity.
- NL-201 had completed GLP toxicology in-life dosing without unexpected toxicity reported. The candidate had not yet been tested in clinical trials; safety, efficacy, regulatory, manufacturing, and financing outcomes remained uncertain.
- The Vancouver office lease ended June 30. The company paid a $0.5 million termination fee and recorded a $0.3 million lease-termination loss and a $0.2 million property-disposal loss.
- The July offering comprised common shares and pre-funded warrants. The July sale of the Canadian subsidiary was expected to create a tax capital-loss carryforward, but the related deferred tax asset was fully valuation-allowed.
- Management concluded disclosure controls were effective at a reasonable-assurance level. No material change in internal control over financial reporting was reported; the transition of accounting and financial-reporting operations to Seattle had been completed.
Important facts for investors to verify
- Confirm the filing entity: the supplied 10-Q is Neoleukin Therapeutics, not Neurogene Inc.
- Review the July 7 offering terms, net proceeds, and dilution from common shares and pre-funded warrants; reconcile the filing’s share counts and weighted-average shares, which include outstanding pre-funded warrants.
- Assess whether the stated runway into 2023 remains supported by actual cash burn, development plans, and any subsequent financing needs.
- Track NL-201’s IND timing and any COVID-19, preclinical, manufacturing, or regulatory delays.
- Review the financial impact and completed accounting for the Canadian subsidiary sale and lease terminations in subsequent filings.